Michael Berger
Ohio State University
32 Papers
198 Citations
Michael Berger is an academic researcher from Ohio State University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 13, co-authored 32 publications. Previous affiliations of Michael Berger include The Ohio State University Wexner Medical Center & James Cancer Hospital.
Chat about Author
Papers
Antiemesis, version 2.2017 featured updates to the NCCN guidelines
Michael Berger,David S. Ettinger,Jonathan Aston,Sally Y. Barbour,Jason J Bergsbaken,Philip J. Bierman,Debra Brandt,Dawn E. Dolan,Georgiana Ellis,Eun-Jeong Kim,Steve Kirkegaard,Dwight D. Kloth,Ruth Lagman,Dean Lim,Charles L. Loprinzi,Cynthia X. Ma,Victoria Maurer,Laura Boehnke Michaud,Lisle Nabell,Kim Noonan,Eric Roeland,Hope S. Rugo,Lee S. Schwartzberg,Bridget Scullion,John P. Timoney,Barbara Todaro,Susan G. Urba,Dorothy A. Shead,Miranda Hughes +28 more
TL;DR: Recent updates to the NCCN Guidelines for Antiemesis, specifically those regarding carboplatin, granisetron, and olanzapine, are focused on.
Antiemesis. Clinical Practice Guidelines in Oncology.
David S. Ettinger,Debra K. Armstrong,Sally Y. Barbour,Michael Berger,Philip J. Bierman,Bob Bradbury,Georgianna Ellis,Steve Kirkegaard,Dwight D. Kloth,Mark G. Kris,Dean Lim,Michael Anne Markiewicz,Lida Nabati,Carli Nesheiwat,Hope S. Rugo,Steven Sorscher,Lisa Stucky-Marshal,Barbara Todaro,Susan G. Urba +18 more
Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients
Maryam B. Lustberg,Priya Balasubramanian,Brandon Miller,Alejandra Garcia-Villa,Clayton Deighan,Yongqi Wu,Sarah Carothers,Michael Berger,Bhuvaneswari Ramaswamy,Erin Macrae,Robert Wesolowski,Rachel M. Layman,Ewa Mrozek,Xueliang Pan,Thomas A. Summers,Charles L. Shapiro,Jeffrey J. Chalmers +16 more
TL;DR: This prospective trial characterized CTCs as well as other circulating cell populations in blood samples from women with metastatic breast cancer without EpCAM-dependent enrichment and/or isolation technology and found that atypical cells that are CK + EpCAM − circulating in their blood are associated with worse overall survival.
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab
Hannah Dzimitrowicz,Michael Berger,Craig A. Vargo,Annette Hood,Osama Abdelghany,Akshara Singareeka Raghavendra,Debu Tripathy,Vicente Valero,Christos Hatzis,Lajos Pusztai,Rashmi Krishna Murthy +10 more
TL;DR: Tumor response rates were lower than in prior reports of trastuzumab-resistant, HER2-positive MBC, but one third of patients received therapy with T-DM1 for ≥ 6 months, which suggests a clinically relevant benefit in patients who received prior pertuzumabs.
82
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
John M Seligson,Alexandra M Patron,Michael Berger,R. Donald Harvey,Nathan D. Seligson,Nathan D. Seligson +5 more
TL;DR: The pharmacology, efficacy, and safety of sacituzumab govitecan for patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease are reviewed.
48